The abstract is read at the publisher; the summary is JClub's.
Etentamig achieved objective responses in 66% of 146 adult patients with relapsed/refractory multiple myeloma, with ≥very good partial responses in 54%.
- Why it matters: For triple-class–exposed, heavily pretreated patients, durable efficacy with manageable toxicity remains a key unmet need.
- What they did: In pooled phase 1 dose-escalation/expansion (NCT03933735) and phase 1b Arm A (NCT05650632), patients received step-up dosing and then 60 mg Q4W or 40 mg Q3W; median follow-up was 13 months.
- The result: Median duration of response and progression-free survival were not reached, and safety was manageable, with Grade 3/4 neutropenia and infection in 38% and 23%; CRS in phase 1b Arm A occurred in 30% with rapid resolution.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.